{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:29:50Z","timestamp":1790188190756,"version":"4.1.0"},"reference-count":84,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:00:00Z","timestamp":1688083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Taiho Oncology, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Fibroblast growth factor receptors (FGFR) are emerging as an important therapeutic target for patients with advanced, refractory cancers. Most selective FGFR inhibitors under investigation show reversible binding, and their activity is limited by acquired drug resistance. This review summarizes the preclinical and clinical development of futibatinib, an irreversible FGFR1-4 inhibitor. Futibatinib stands out among FGFR inhibitors because of its covalent binding mechanism and low susceptibility to acquired resistance. Preclinical data indicated robust activity of futibatinib against acquired resistance mutations in the FGFR kinase domain. In early-phase studies, futibatinib showed activity in cholangiocarcinoma, and gastric, urothelial, breast, central nervous system, and head and neck cancers harboring various FGFR aberrations. Exploratory analyses indicated clinical benefit with futibatinib after prior FGFR inhibitor use. In a pivotal phase II trial, futibatinib demonstrated durable objective responses (42% objective response rate) and tolerability in previously treated patients with advanced intrahepatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements. A manageable safety profile was observed across studies, and patient quality of life was maintained with futibatinib treatment in patients with cholangiocarcinoma. Hyperphosphatemia, the most common adverse event with futibatinib, was well managed and did not lead to treatment discontinuation. These data show clinically meaningful benefit with futibatinib in FGFR2-rearrangement-positive cholangiocarcinoma and provide support for further investigation of futibatinib across other indications. Future directions for this agent include elucidating mechanisms of resistance and exploration of combination therapy approaches.<\/jats:p>","DOI":"10.1093\/oncolo\/oyad149","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T09:30:27Z","timestamp":1685525427000},"page":"928-943","source":"Crossref","is-referenced-by-count":39,"title":["Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of\n                    <i>FGFR<\/i>\n                    -Aberrant Tumors"],"prefix":"10.1093","volume":"28","author":[{"given":"Milind","family":"Javle","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Oncology, University of Texas MD Anderson Cancer Center , Houston, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gentry","family":"King","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, University of Washington , Seattle, WA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5577-3439","authenticated-orcid":false,"given":"Kristen","family":"Spencer","sequence":"additional","affiliation":[{"name":"Perlmutter Cancer Center of NYU Langone Health , New York, NY , USA"},{"name":"NYU Grossman School of Medicine, New York University , New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitesh J","family":"Borad","sequence":"additional","affiliation":[{"name":"Department of Oncology , Mayo Clinic Cancer Center, Phoenix, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,6,30]]},"reference":[{"issue":"12","key":"2023110708532995800_CIT0001","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-14-2329","article-title":"Targeting FGFR signaling in cancer","volume":"21","author":"Touat","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2023110708532995800_CIT0002","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/hep.26890","article-title":"Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma","volume":"59","author":"Arai","year":"2014","journal-title":"Hepatology"},{"key":"2023110708532995800_CIT0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00080","article-title":"Cholangiocarcinoma with FGFR genetic aberrations: a unique clinical phenotype","volume":"2","author":"Jain","year":"2018","journal-title":"JCO Precis Oncol."},{"issue":"12","key":"2023110708532995800_CIT0004","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.3390\/cancers12123825","article-title":"Role of fibroblast growth factors receptors (FGFRS) in brain tumors, focus on astrocytoma and glioblastoma","volume":"12","author":"Ardizzone","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"13","key":"2023110708532995800_CIT0005","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1158\/1078-0432.CCR-13-0190","article-title":"Targeting FGFR with dovitinib (tki258): preclinical and clinical data in breast cancer","volume":"19","author":"Andr\u00e9","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2023110708532995800_CIT0006","first-page":"3541","article-title":"Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers","volume":"61","author":"Jang","year":"2001","journal-title":"Cancer Res"},{"issue":"9","key":"2023110708532995800_CIT0007","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1158\/1078-0432.CCR-12-3898","article-title":"FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547","volume":"19","author":"Xie","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2023110708532995800_CIT0008","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2023110708532995800_CIT0009","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","article-title":"Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma","volume":"7","author":"Goyal","year":"2017","journal-title":"Cancer Discov"},{"issue":"5","key":"2023110708532995800_CIT0010","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41416-020-01157-0","article-title":"Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance","volume":"124","author":"Krook","year":"2021","journal-title":"Br J Cancer"},{"issue":"22","key":"2023110708532995800_CIT0011","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.1158\/0008-5472.CAN-19-2568","article-title":"Futibatinib is a novel irreversible FGFR 1-4 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors","volume":"80","author":"Sootome","year":"2020","journal-title":"Cancer Res"},{"issue":"23","key":"2023110708532995800_CIT0012","doi-asserted-by":"crossref","first-page":"15694","DOI":"10.1074\/jbc.M601252200","article-title":"Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family","volume":"281","author":"Zhang","year":"2006","journal-title":"J Biol Chem"},{"issue":"2","key":"2023110708532995800_CIT0013","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: from development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"2023110708532995800_CIT0014","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1242\/dev.127.3.483","article-title":"An important role for the IIIb isoform of fibroblast growth factor receptor 2 (FGFR2) in mesenchymal-epithelial signalling during mouse organogenesis","volume":"127","author":"De Moerlooze","year":"2000","journal-title":"Development"},{"issue":"13","key":"2023110708532995800_CIT0015","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1242\/dev.00491","article-title":"Conditional inactivation of FGF receptor 2 reveals an essential role for FGF signaling in the regulation of osteoblast function and bone growth","volume":"130","author":"Yu","year":"2003","journal-title":"Development"},{"issue":"4","key":"2023110708532995800_CIT0016","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/ng0496-390","article-title":"Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3","volume":"12","author":"Colvin","year":"1996","journal-title":"Nat Genet"},{"issue":"21","key":"2023110708532995800_CIT0017","doi-asserted-by":"crossref","first-page":"7600","DOI":"10.1128\/MCB.23.21.7600-7610.2003","article-title":"Fibroblast growth factor 2-mediated translational control of IAPs blocks mitochondrial release of Smac\/DIABLO and apoptosis in small cell lung cancer cells","volume":"23","author":"Pardo","year":"2003","journal-title":"Mol Cell Biol"},{"issue":"13","key":"2023110708532995800_CIT0018","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1038\/sj.emboj.7601198","article-title":"Fgf-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2","volume":"25","author":"Pardo","year":"2006","journal-title":"EMBO J"},{"issue":"8","key":"2023110708532995800_CIT0019","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.7150\/jca.40531","article-title":"FGF\/FGFR signaling pathway involved resistance in various cancer types","volume":"11","author":"Zhou","year":"2020","journal-title":"J Cancer"},{"issue":"11","key":"2023110708532995800_CIT0020","first-page":"4514","article-title":"High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer","volume":"61","author":"Simon","year":"2001","journal-title":"Cancer Res"},{"issue":"12","key":"2023110708532995800_CIT0021","doi-asserted-by":"crossref","first-page":"e115383","DOI":"10.1371\/journal.pone.0115383","article-title":"Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications","volume":"9","author":"Churi","year":"2014","journal-title":"PLoS One"},{"issue":"13","key":"2023110708532995800_CIT0022","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1016\/j.celrep.2017.06.008","article-title":"Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles","volume":"19","author":"Farshidfar","year":"2017","journal-title":"Cell Rep"},{"issue":"19","key":"2023110708532995800_CIT0023","first-page":"4360","article-title":"Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups","volume":"57","author":"Courjal","year":"1997","journal-title":"Cancer Res"},{"issue":"1","key":"2023110708532995800_CIT0024","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrc3817","article-title":"Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity","volume":"15","author":"Knowles","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"2023110708532995800_CIT0025","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1097\/JTO.0b013e31826aed28","article-title":"FGFR1 amplification in squamous cell carcinoma of the lung","volume":"7","author":"Heist","year":"2012","journal-title":"J Thorac Oncol"},{"issue":"2","key":"2023110708532995800_CIT0026","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/modpathol.2013.141","article-title":"Fibroblast growth factor receptor 1 (FGFR1) amplification is a potential therapeutic target in small-cell lung cancer","volume":"27","author":"Schultheis","year":"2014","journal-title":"Mod Pathol"},{"issue":"6099","key":"2023110708532995800_CIT0027","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1126\/science.1220834","article-title":"Transforming fusions of FGFR and TACC genes in human glioblastoma","volume":"337","author":"Singh","year":"2012","journal-title":"Science"},{"issue":"4","key":"2023110708532995800_CIT0028","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/bjc.2013.802","article-title":"FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study","volume":"110","author":"Su","year":"2014","journal-title":"Br J Cancer"},{"issue":"5","key":"2023110708532995800_CIT0029","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/bjc.2014.61","article-title":"HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma","volume":"110","author":"Liu","year":"2014","journal-title":"Br J Cancer"},{"issue":"4","key":"2023110708532995800_CIT0030","doi-asserted-by":"crossref","first-page":"152878","DOI":"10.1016\/j.prp.2020.152878","article-title":"High-level FGFR2 amplification is associated with poor prognosis and lower response to chemotherapy in gastric cancers","volume":"216","author":"Hur","year":"2020","journal-title":"Pathol Res Pract"},{"issue":"25","key":"2023110708532995800_CIT0031","doi-asserted-by":"crossref","first-page":"8713","DOI":"10.1073\/pnas.0803379105","article-title":"Drug-sensitive FGFR2 mutations in endometrial carcinoma","volume":"105","author":"Dutt","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"2023110708532995800_CIT0032","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1182\/blood.V97.3.729","article-title":"Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma","volume":"97","author":"Chesi","year":"2001","journal-title":"Blood"},{"issue":"1","key":"2023110708532995800_CIT0033","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1476-4598-4-15","article-title":"Clinical and biological characteristics of cervical neoplasias with FGFR3 mutation","volume":"4","author":"Rosty","year":"2005","journal-title":"Mol Cancer"},{"issue":"6","key":"2023110708532995800_CIT0034","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/modpathol.2009.46","article-title":"FGFR3 mutations in prostate cancer: association with low-grade tumors","volume":"22","author":"Hernandez","year":"2009","journal-title":"Mod Pathol"},{"issue":"11","key":"2023110708532995800_CIT0035","doi-asserted-by":"crossref","first-page":"e0141867","DOI":"10.1371\/journal.pone.0141867","article-title":"FGFR1 amplification is often homogeneous and strongly linked to the squamous cell carcinoma subtype in esophageal carcinoma","volume":"10","author":"von Loga","year":"2015","journal-title":"PLoS One"},{"issue":"15","key":"2023110708532995800_CIT0036","doi-asserted-by":"crossref","first-page":"8675","DOI":"10.3390\/ijms23158675","article-title":"FGFR3-TACCs3 fusions and their clinical relevance in human glioblastoma","volume":"23","author":"G\u00f6tt","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"20","key":"2023110708532995800_CIT0037","doi-asserted-by":"crossref","first-page":"5619","DOI":"10.1158\/1078-0432.CCR-21-1414","article-title":"Circulating tumor DNA analysis detects FGFR2 amplification and concurrent genomic alterations associated with FGFR inhibitor efficacy in advanced gastric cancer","volume":"27","author":"Jogo","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2023110708532995800_CIT0038","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ccell.2017.12.004","article-title":"Clinical sequencing defines the genomic landscape of metastatic colorectal cancer","volume":"33","author":"Yaeger","year":"2018","journal-title":"Cancer Cell"},{"issue":"2","key":"2023110708532995800_CIT0039","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41571-018-0115-y","article-title":"Fibroblast growth factor receptors as treatment targets in clinical oncology","volume":"16","author":"Katoh","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"2023110708532995800_CIT0040","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3390\/cells8060614","article-title":"Fibroblast growth factor receptors (FGFRs): structures and small molecule inhibitors","volume":"8","author":"Dai","year":"2019","journal-title":"Cells"},{"issue":"10","key":"2023110708532995800_CIT0041","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.jtho.2019.05.041","article-title":"SWOG S1400D (NCT02965378), a phase II study of the fibroblast growth factor receptor inhibitor AZD4547 in previously treated patients with fibroblast growth factor pathway-activated stage iv squamous cell lung cancer (lung-map substudy)","volume":"14","author":"Aggarwal","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"21","key":"2023110708532995800_CIT0042","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1200\/JCO.19.02630","article-title":"Phase II study of AZD4547 in patients with tumors harboring aberrations in the FGFR pathway: results from the NCI-MATCH trial (EAY131) subprotocol W","volume":"38","author":"Chae","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"2023110708532995800_CIT0043","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41416-018-0334-0","article-title":"Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma","volume":"120","author":"Mazzaferro","year":"2019","journal-title":"Br J Cancer"},{"issue":"9","key":"2023110708532995800_CIT0044","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1158\/1078-0432.CCR-18-1959","article-title":"A phase I, open-label, multicenter, dose-escalation study of the oral selective FGFR inhibitor debio 1347 in patients with advanced solid tumors harboring FGFR gene alterations","volume":"25","author":"Voss","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"15_suppl","key":"2023110708532995800_CIT0045","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2019.37.15_suppl.4117","article-title":"Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations","volume":"37","author":"Park","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"2023110708532995800_CIT0046","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"2023110708532995800_CIT0047","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1158\/2159-8290.CD-19-0555","article-title":"First-in-human phase I study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma","volume":"9","author":"Kim","year":"2019","journal-title":"Cancer Discov"},{"issue":"3","key":"2023110708532995800_CIT0048","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N Engl J Med"},{"issue":"10","key":"2023110708532995800_CIT0049","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","article-title":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: Mature results from a multicentre, open-label, single-arm, phase 2 study","volume":"6","author":"Javle","year":"2021","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"7","key":"2023110708532995800_CIT0050","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1158\/2159-8290.CD-18-0229","article-title":"Efficacy of BGJ398, a fibroblast growth factor receptor 1-3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations","volume":"8","author":"Pal","year":"2018","journal-title":"Cancer Discov"},{"issue":"5","key":"2023110708532995800_CIT0051","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"2023110708532995800_CIT0052","first-page":"viii319VIII319","article-title":"Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)\/FGF receptor (FGFR) genetic alterations (GA)","volume":"29","author":"Necchi","year":"2018","journal-title":"Ann Oncol"},{"issue":"10","key":"2023110708532995800_CIT0053","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(19)30412-7","article-title":"Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study","volume":"20","author":"Schuler","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"2023110708532995800_CIT0054","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/cmdc.201800719","article-title":"TAS-120 cancer target binding: defining reactivity and revealing the first fibroblast growth factor receptor 1 (FGFR1) irreversible structure","volume":"14","author":"Kalyukina","year":"2019","journal-title":"ChemMedChem"},{"issue":"10","key":"2023110708532995800_CIT0055","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1158\/2159-8290.CD-20-1669","article-title":"FGFR2 extracellular domain in-frame deletions are therapeutically targetable genomic alterations that function as oncogenic drivers in cholangiocarcinoma","volume":"11","author":"Cleary","year":"2021","journal-title":"Cancer Discov"},{"issue":"3","key":"2023110708532995800_CIT0056","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-19-0631","article-title":"Efficacy of FGFR inhibitors and combination therapies for acquired resistance in FGFR2-fusion cholangiocarcinoma","volume":"19","author":"Krook","year":"2020","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"2023110708532995800_CIT0057","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/2159-8290.CD-20-0766","article-title":"Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib","volume":"11","author":"Silverman","year":"2021","journal-title":"Cancer Discov"},{"issue":"5","key":"2023110708532995800_CIT0058","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.molcel.2007.06.028","article-title":"A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases","volume":"27","author":"Chen","year":"2007","journal-title":"Mol Cell"},{"key":"2023110708532995800_CIT0059","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1158\/1538-7445.AM2021-1117","article-title":"Acquired resistance to ATP-competitive and irreversible FGFR inhibitors (FGFRi's): a library-based approach","volume":"81","author":"Sootome","year":"2021","journal-title":"Cancer Res"},{"issue":"8","key":"2023110708532995800_CIT0060","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1158\/2159-8290.CD-19-0182","article-title":"Tas-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma","volume":"9","author":"Goyal","year":"2019","journal-title":"Cancer Discov"},{"issue":"10","key":"2023110708532995800_CIT0061","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.annonc.2020.06.018","article-title":"Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors","volume":"31","author":"Bahleda","year":"2020","journal-title":"Ann Oncol"},{"issue":"10","key":"2023110708532995800_CIT0062","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1002\/jbmr.478","article-title":"FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone","volume":"26","author":"Wohrle","year":"2011","journal-title":"J Bone Miner Res"},{"key":"2023110708532995800_CIT0063","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/cas.15486","article-title":"Phase I study of the irreversible fibroblast growth factor receptor 1-4 inhibitor futibatinib in Japanese patients with advanced solid tumors","volume":"114","author":"Doi","year":"2023","journal-title":"Cancer Sci"},{"key":"2023110708532995800_CIT0064","article-title":"Phase 1, open-label studies of futibatinib excretion, metabolic profiling, and food effects in healthy adult volunteers","author":"Yamamiya"},{"issue":"13_Supplement","key":"2023110708532995800_CIT0065","doi-asserted-by":"crossref","first-page":"CT125","DOI":"10.1158\/1538-7445.AM2021-CT125","article-title":"Evaluation of potential drug\u2013drug interactions (DDIs) between futibatinib and cyp3a inhibitors\/inducers, CYP3A substrates, or proton pump inhibitors (PPIs)","volume":"81","author":"Yamamiya","year":"2021","journal-title":"Cancer Res"},{"issue":"4","key":"2023110708532995800_CIT0066","first-page":"263","article-title":"Basic review of the cytochrome p450 system","volume":"4","author":"McDonnell","year":"2013","journal-title":"J Adv Pract Oncol"},{"issue":"2","key":"2023110708532995800_CIT0067","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1158\/2159-8290.CD-21-0697","article-title":"Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF\/FGFR aberrations: a phase I dose-expansion study","volume":"12","author":"Meric-Bernstam","year":"2022","journal-title":"Cancer Discov"},{"issue":"16_suppl","key":"2023110708532995800_CIT0068","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1200\/JCO.2022.40.16_suppl.4009","article-title":"Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions\/rearrangements","volume":"40","author":"Goyal","year":"2022","journal-title":"J Clin Oncol"},{"key":"2023110708532995800_CIT0069","volume-title":"Lytgobi (futibatinib) tablets, for oral use [prescribing information]","year":"2022"},{"issue":"13","key":"2023110708532995800_CIT0070","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1182\/bloodadvances.2020002308","article-title":"Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia","volume":"4","author":"Kasbekar","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"2023110708532995800_CIT0071","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1200\/JCO.2016.67.2048","article-title":"Evaluation of BGJ398, a fibroblast growth factor receptor 1-3 kinase inhibitor, in patients with advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors: Results of a global phase i, dose-escalation and dose-expansion study","volume":"35","author":"Nogova","year":"2017","journal-title":"J Clin Oncol"},{"key":"2023110708532995800_CIT0072","volume-title":"Futibatinib and pembrolizumab combination in the treatment of advanced or metastatic urothelial carcinoma. ClinicalTrial.gov identifier NCT04601857"},{"issue":"3","key":"2023110708532995800_CIT0073","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","article-title":"Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma","volume":"36","author":"Javle","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3_suppl","key":"2023110708532995800_CIT0074","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1200\/JCO.2021.39.3_suppl.265","article-title":"Final results from a phase ii study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement","volume":"39","author":"Javle","year":"2021","journal-title":"J Clin Oncol"},{"issue":"9","key":"2023110708532995800_CIT0075","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s11912-021-01100-3","article-title":"FGFR inhibitors: clinical activity and development in the treatment of cholangiocarcinoma","volume":"23","author":"King","year":"2021","journal-title":"Curr Oncol Rep"},{"issue":"12","key":"2023110708532995800_CIT0076","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.3390\/cancers13122968","article-title":"FGFR inhibitors in oncology: insight on the management of toxicities in clinical practice","volume":"13","author":"Kommalapati","year":"2021","journal-title":"Cancers"},{"issue":"2","key":"2023110708532995800_CIT0077","doi-asserted-by":"crossref","first-page":"e316","DOI":"10.1002\/onco.13552","article-title":"Dermatologic adverse events associated with selective fibroblast growth factor receptor inhibitors: overview, prevention, and management guidelines","volume":"26","author":"Lacouture","year":"2021","journal-title":"Oncologist"},{"key":"2023110708532995800_CIT0078","doi-asserted-by":"crossref","first-page":"S378S376","DOI":"10.1016\/j.annonc.2021.08.330","article-title":"Pooled analysis safety profile of futibatinib in patients with advanced solid tumors, including intrahepatic cholangiocarcinoma","volume":"32","author":"Meric-Bernstam","year":"2021","journal-title":"Ann Oncol"},{"issue":"15_suppl","key":"2023110708532995800_CIT0079","doi-asserted-by":"crossref","first-page":"e15623","DOI":"10.1200\/JCO.2019.37.15_suppl.e15623","article-title":"Health-related quality-of-life in patients with cholangiocarcinoma: results of a systematic literature review","volume":"37","author":"Cho","year":"2019","journal-title":"J Clin Oncol"},{"issue":"9","key":"2023110708532995800_CIT0080","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1158\/2326-6066.CIR-18-0595","article-title":"The combined effect of FGFR inhibition and PD-1 blockade promotes tumor-intrinsic induction of antitumor immunity","volume":"7","author":"Palakurthi","year":"2019","journal-title":"Cancer Immunol Res."},{"issue":"16_Supplement","key":"2023110708532995800_CIT0081","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1158\/1538-7445.AM2020-661","article-title":"Abstract 661: synergistic antitumor activity of futibatinib, an FGFR1-4 inhibitor, and TAS-117, a selective AKT inhibitor, in FGFR-deregulated cancer models","volume":"80","author":"Iwasaki","year":"2020","journal-title":"Cancer Res"},{"issue":"16_Supplement","key":"2023110708532995800_CIT0082","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1158\/1538-7445.AM2020-564","article-title":"Abstract 564: Futibatinib (TAS-120) plus chemotherapy demonstrates a synergistic effect across various FGFR-deregulated cancer cell lines and xenograft models","volume":"80","author":"Sootome","year":"2020","journal-title":"Cancer Res"},{"issue":"16_Supplement","key":"2023110708532995800_CIT0083","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1158\/1538-7445.AM2020-659","article-title":"Abstract 659: synergistic antitumor activity of futibatinib (TAS-120), a FGFR1-4 inhibitor, and PI3K pathway inhibitors","volume":"80","author":"Miura","year":"2020","journal-title":"Cancer Res"},{"issue":"19","key":"2023110708532995800_CIT0084","doi-asserted-by":"crossref","first-page":"6130","DOI":"10.1158\/1078-0432.CCR-11-0659","article-title":"Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis","volume":"17","author":"Lieu","year":"2011","journal-title":"Clin Cancer Res"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/11\/928\/52772321\/oyad149.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/11\/928\/52772321\/oyad149.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T08:30:20Z","timestamp":1702542620000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/11\/928\/7216373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,30]]},"references-count":84,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,6,30]]},"published-print":{"date-parts":[[2023,11,2]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad149","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11,1]]},"published":{"date-parts":[[2023,6,30]]}}}